Clinical Study
Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
Table 1
Demographic/clinical analysis of AC-MS, WA-MS, and AA-MS of EVIDENCE study.
| | Clinical/demographic Information | AC-MS | WA-MS (EVIDENCE) | AA-MS (EVIDENCE) |
| | Female, % | 77.6 | 74.5 | 86.1 |
| | Mean age at first symptom, years (range) | 30.1 (14–50) | 31.8 (18–55) | 32.1 (18–55) |
| | Mean disease duration, years (median) | 4.7 (2) | 6.9 | 5.6 |
| | Mean treatment duration, weeks | 153.2 | 62 | 62 |
| | Mean EDSS at treatment (median) | 2.52 (2.5) | 2.3 | 2.8 |
| | Mean number of relapses in the 2 previous years (median) | 2.3 (2) | 2.6 | 2.5 |
| | %, relapse free at 48 weeks | 46.2 | 57 | 47 |
|
|
